Suven Life Sciences secures product patents

Suven Life Sciences on Friday informed the bourses that it has secured one product patent from Eurasia, one product patent from Europe, one product patent from South Korea and one product patent from Sri Lanka corresponding to the New Chemical Entities for the treatment of disorders associated with Neurodegenerative diseases and patents are valid through 2034.

The granted claims of the patents include the class of selective 5-HT6 compounds and are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercialising novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.

The stock of Suven Life Science in the Friday’s trading session was trading on a positive note. The stock which opened at Rs. 264.55 apiece, touched an intra-day high of Rs. 266.90. At 12:07 hours, the stock was trading at Rs. 264.40 apiece, up by 0.90 per cent from its previous close.